Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Beyond LDL-C: Three Complex Cases

A 2026 case-based review shows how ApoB, particle measures, imaging and genetics can add context when LDL-C tells only part of the story.

Why we wrote this. The review appeared in a tirzepatide scout, but its useful lesson is broader: lipid phenotypes can contain information that LDL-C alone does not show.

In this article (5 sections)
  1. The three cases expose different blind spots
  2. ApoB answers a particle question
  3. The review proposes a layered assessment
  4. The incretin reference has strict limits
  5. What the paper cannot establish

A case-based review published online on 22 October 2026 argues that LDL cholesterol alone can miss clinically relevant differences in atherogenic particle burden and inherited disease, as well as metabolic risk and treatment response. Authors Niki M. Fanaropoulou and Roshni T. Varghese use three patient phenotypes to show why a lipid result that looks close to target may still leave questions about particle number or family history, with imaging and genetics adding context in selected cases[1].

This publication is a case-based review, not a randomized trial. It reports no treatment effect estimate, comparison group, or clinical outcome endpoint. Its contribution is diagnostic reasoning: each case exposes information that LDL-C did not capture on its own. The review then proposes a phenotype-driven assessment that combines standard cholesterol measures with selected tests and clinical context[1].

The three cases expose different blind spots

The first case describes a patient with subclinical coronary atherosclerosis whose LDL-C stayed near conventional targets while diet-sensitive LDL particle measures and a lipoprotein insulin resistance score changed. LDL particle number estimates the concentration of LDL particles, while LDL-C measures the cholesterol carried inside them. The insulin resistance score combines lipoprotein measurements into a metabolic marker. In this phenotype, the review asks clinicians to read those signals alongside diet response and imaging without treating one LDL-C value as the whole risk picture[1].

The second case involves obesity, a strong family history, and persistently low HDL-C and HDL particle number despite a substantial fall in LDL-C with non-statin and incretin-era therapies. The PubMed abstract does not name the incretin drug, its dose, or the sequence of treatment. Readers should therefore avoid assigning this case to tirzepatide or any other specific medicine. The case supports a narrower observation: improvement in LDL-C did not normalize every measured lipid feature[1].

The third case describes familial hypercholesterolemia confirmed by a pathogenic LDLR variant even though the patient lacked classic physical signs. LDLR is the gene that encodes the LDL receptor, which helps clear LDL particles from blood. The case shows why the absence of visible stigmata cannot by itself exclude an inherited lipid disorder when the family and laboratory pattern still raise suspicion[1].

ApoB answers a particle question

Apolipoprotein B, usually shortened to ApoB, is the main structural protein carried by atherogenic lipoprotein particles. Because each of these particles carries one ApoB molecule, ApoB can act as a count of the particles capable of entering the artery wall. LDL-C answers a different question: how much cholesterol is contained within LDL particles. The two measurements often move together, but the case review focuses on situations in which their information may diverge[1].

A separate 2026 peer-reviewed article by Allan D. Sniderman argues that ApoB has stronger evidence than LDL-C or non-HDL-C for assessing cardiovascular risk and the adequacy of lipid-lowering therapy. It also says ApoB is important for diagnosing type III hyperlipoproteinemia and familial combined hyperlipidemia. That article criticizes the gap between this evidence and the limited role ApoB receives in clinical recommendations[2]. This is an argument about how to measure risk, not evidence that LDL-C has stopped being useful.

The review proposes a layered assessment

The authors propose integrating LDL-C with ApoB or LDL particle number, diet response, metabolic context, imaging, medication tolerance, and selective genetic testing. Their framework does not mean ordering every test for every patient. The word selective is central to the genetic component, and the cases show different reasons for adding information: unexplained particle discordance, a metabolic phenotype that persists after LDL-C falls, or a pattern consistent with inherited disease[1].

Imaging occupies a separate place in that framework. In the first case, subclinical coronary atherosclerosis was already present, so the lipid measurements were interpreted alongside evidence of disease. The abstract does not specify the imaging method, score, or threshold. It supports using imaging context, but it cannot support a particular scan schedule or a universal trigger for further testing[1].

The incretin reference has strict limits

The phrase "incretin-era therapies" appears only in the description of the second case. The abstract does not report which therapy was used, whether weight changed, how long treatment lasted, or whether the therapy caused the lipid pattern. It also does not compare one incretin medicine with another. The paper therefore cannot answer whether tirzepatide improves ApoB, HDL particle number, or cardiovascular outcomes in people with this phenotype[1].

Our tirzepatide regulation and evidence page covers the drug under its own trial and regulatory sources. That material should remain separate from this case review. A broad treatment-era label is not enough to identify a molecule, establish causation, or justify a change in treatment.

What the paper cannot establish

Three selected cases can illustrate clinical reasoning, but they cannot estimate how often LDL-C and particle measures disagree in the wider population. They cannot show that a phenotype-driven strategy prevents more cardiovascular events than standard care. The abstract also provides no protocol for choosing tests, no treatment algorithm, and no comparison of costs or harms from wider testing[1].

The paper is most useful as a prompt for better questions when the clinical picture and LDL-C do not line up. ApoB, particle number, imaging, metabolic context, and genetics each answer a different question. Which of those questions is relevant depends on the patient's history and existing results. Decisions about additional testing or treatment belong with a qualified clinician who can interpret the full record.

Frequently asked

What is the difference between LDL-C and ApoB?

LDL-C measures the cholesterol carried inside LDL particles. ApoB reflects the number of atherogenic lipoprotein particles because each carries one ApoB molecule. They often track together, but the review examines cases in which particle information may add context.

Does this review say LDL-C is no longer useful?

No. The authors propose combining LDL-C with selected information such as ApoB or LDL particle number, metabolic context, imaging, medication tolerance, diet response, and genetic testing when the phenotype calls for it.

Was tirzepatide used in one of the cases?

The PubMed abstract refers to non-statin and incretin-era therapies but does not identify a drug, dose, treatment duration, or sequence. The case cannot be assigned to tirzepatide from the available abstract.

Sources

  1. [1]Fanaropoulou and Varghese (2026): Beyond LDL-C: A Case-Based Review of Complex Dyslipidemia (PMID 42914050)Tier 1 · primary↩
  2. [2]Sniderman (2026): Is the Commitment to LDL-C Eternal? (PMID 42761924)Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars